FBRX - NASDAQ
Forte Biosciences, Inc.
$16.74
-7.9%Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
At a Glance
Live SnapshotForte Biosciences, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Forte Biosciences, Inc. Cash Flow Statement
FBRX • NASDAQ
| Forte Biosciences, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||||||
-69.4M | -35.5M | -31.5M | -13.9M | -21.7M | -46.5M | -4.1M | -49M | -38.9M | -33.5M | -23.1M | |
64K | 39K | 9K | 0.0 | 36K | 54K | 11K | 625K | 292K | 255K | 232K | |
1M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 918K | -6.9M | -4.5M | 0.0 | 0.0 | |
6.3M | 3.1M | 3.3M | 4M | 4.2M | 956K | 35.7K | 6.9M | 4.5M | 0.0 | 0.0 | |
-237K | -158K | -131K | 0.0 | 61K | 30.9M | -918K | 7.8M | 5.3M | 1.7M | 928K | |
11.4M | 1.8M | -392K | 1.7M | 720K | -3.8M | 1.3M | 6.1M | 2.5M | 1.9M | 747K | |
-50.9M | -30.7M | -28.7M | -8.2M | -16.7M | -18.4M | -2.8M | -34.5M | -31.1M | -29.5M | -21M | |
INVESTING ACTIVITIES | |||||||||||
-116K | -37K | -88K | (0.0) | (0.0) | (0.0) | -161.6K | -2M | -655K | -525K | -231K | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (3.6K) | (0.0) | (2.2M) | (20K) | (0.0) | (15K) | |
(0.0) | -36M | -10M | (0.0) | (0.0) | (0.0) | (0.0) | -70.7M | -70.8M | -23M | -59.9M | |
36.4M | 0.0 | 10.1M | 0.0 | 0.0 | 0.0 | 0.0 | 68.5M | 43.7M | 48.1M | 35.2M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.6M | 42.3M | -2.2M | -27.1M | 25.1M | -24.7M | |
(36.2M) | -36M | (47K) | (0.0) | (0.0) | (3.6M) | -161.6K | -4.2M | -27.7M | (24.6M) | -24.9M | |
FINANCING ACTIVITIES | |||||||||||
76.8M | 53M | 24.7M | 7.2M | 62K | 66.7M | 0.0 | 28.8M | 89.1M | 10K | 157K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 23.3M | 138K | 2.9M | 50.7M | |
(0.0) | -1K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (89K) | (3.4M) | (33.2M) | |
-7.5M | -1.1M | -44K | 12K | -106K | -32K | 4.9M | -8.6M | 0.0 | -592K | -982K | |
69.4M | 51.9M | 24.7M | 7.2M | -44K | 66.7M | 4.9M | 43.5M | 89.3M | 2.3M | 49.9M | |
CASH FLOW SUMMARY | |||||||||||
54.7M | -14.9M | -4M | -944K | -16.7M | 51.8M | 1.9M | 4.9M | 30.4M | -2.6M | 3.9M | |
22.2M | 37.1M | 41.1M | 42M | 58.8M | 6.9M | 5M | 35.9M | 5.5M | 8.2M | 4.2M | |
77M | 22.2M | 37.1M | 41.1M | 42M | 58.8M | 6.9M | 40.8M | 35.9M | 5.5M | 8.2M | |
-51M | -30.8M | -28.8M | -8.2M | -16.7M | -18.4M | -2.9M | -36.4M | -31.8M | -30.1M | -21.3M |
SEC Filings
FBRX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 02, 2026 | May 29, 2026 | 2026 | |
S-3 S-3 N/A | June 02, 2026 | June 02, 2026 | ||
8-K 8-K 2026 N/A | May 14, 2026 | May 11, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 11, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | May 29, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 09, 2026 | April 08, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 01, 2026 | March 31, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 31, 2026 | December 31, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 14, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 14, 2025 | November 14, 2025 | 2025 |
Related Guides
Continue your FBRX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.